Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH. Sylvester RJ, et al. Among authors: kurth kh. Urology. 2005 Dec;66(6 Suppl 1):90-107. doi: 10.1016/j.urology.2005.06.135. Urology. 2005. PMID: 16399418 Review.
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. de Reijke TM, et al. Among authors: kurth kh. J Urol. 2005 Feb;173(2):405-9. doi: 10.1097/01.ju.0000150425.09317.67. J Urol. 2005. PMID: 15643181 Clinical Trial.
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ; EORTC Genito-Urinary Tract Cancer Collaborative Group. Brausi M, et al. Eur Urol. 2002 May;41(5):523-31. doi: 10.1016/s0302-2838(02)00068-4. Eur Urol. 2002. PMID: 12074794
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R. Bouffioux C, et al. Among authors: kurth kh. J Urol. 1995 Mar;153(3 Pt 2):934-41. J Urol. 1995. PMID: 7853578 Clinical Trial.
A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.
Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. Oosterlinck W, et al. Among authors: kurth kh. J Urol. 1993 Apr;149(4):749-52. doi: 10.1016/s0022-5347(17)36198-0. J Urol. 1993. PMID: 8455236 Clinical Trial.
Phase II trials in Ta, T1 bladder cancer. The marker tumour concept.
van der Meijden AP, Hall RR, Kurth KH, Bouffioux C, Sylvester R. van der Meijden AP, et al. Among authors: kurth kh. Br J Urol. 1996 May;77(5):634-7. doi: 10.1046/j.1464-410x.1996.09002.x. Br J Urol. 1996. PMID: 8689102 Review. No abstract available.
167 results